Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Clinical trial NCT03666000 · RECRUITING
Trial details
- NCT number
- NCT03666000
- Sponsor
- Imugene Limited
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-11
- Primary completion
- 2027-06-01
- Enrollment
- 135
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.